Acquired von Willebrand Disease in Monoclonal Gammapathies: Effectiveness of High-Dose Intravenous Gammaglobulin

  • J. J. Michiels
Conference paper


Acquired von Willebrand disease (AvWD) is a bleeding disorder strikingly similar to congenital von Willebrand disease in terms of clinical manifestations and laboratory findings being characterized by a prolonged bleeding time and low levels of factor VIII von Willebrand factor (FVIII/vWf) complex, but without a family history of a congenital bleeding tendency and absence of abnormal bleeding after hemostatic challenges.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ivy AC, Nelson D, Bucher GNH (1941) The standardization of certain factors in the cutaneous “venostasis” bleeding time technique. J Lab Clin Med 26: 1812Google Scholar
  2. 2.
    van Genderen PJJ, Vink T, Michiels JJ, van’t Veer MB, Sixma JJ, van Vliet HHDM (1994) Acquired von Willebrand disease caused by an autoantibody selectively inhibiting the binding of the von Willebrand factor to collagen. Blood 84: 3378PubMedGoogle Scholar
  3. 3.
    Ceika J (1982) Enzyme immunoassay for FVIII-related antigen Clin Chem 26: 1812Google Scholar
  4. 4.
    Macfarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson JA (1975) A method for assaying von Willebrand factor ( Ristocetine cofactor ). Thromb Diath Haemorrh 34: 306Google Scholar
  5. 5.
    Brown JE, Bosak JO (1986) An ELISA test for the binding of von Willebrand antigen to collagen. Thromb Res 43: 303PubMedCrossRefGoogle Scholar
  6. 6.
    Brosstad F, Kjönniksen I, Rönning B, Stormorken H (1986) Visualization of von Willebrand factor multimers by enzyme-conjugated secondary antibodies. Thromb Haemost 55: 276PubMedGoogle Scholar
  7. 7.
    Kaspar CK, Aledort LM, Counts RB et al (1975) A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34: 869Google Scholar
  8. 8.
    van Genderen PJJ, Michiels JJ, Bakker JJ, van’t Veer MB (1994) Effectiveness of high-dose intravenous gammaglobulin therapy in acquired von Willebrand’s disease. Vox Sang 67: 14PubMedCrossRefGoogle Scholar
  9. 9.
    van Genderen PJJ, Papatsonis DNM, Michiels JJ, Wielenga JJ, Stibbe J, Huikeshoven FJM (1994) High-dose intravenous gammaglobulin therapy for acquired von Willebrand disease. Postgrad Med J 70: 916PubMedCrossRefGoogle Scholar
  10. 10.
    van Genderen PJJ, Terpstra W, Michiels JJ, Kapteijn L, van Vliet HHDD (1995) High-dose intravenous immunoglobulin delays clearance of von Willebrand factor in acquired von Willebrand disease. Thromb Haemost 73: 890Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • J. J. Michiels

There are no affiliations available

Personalised recommendations